CLINICAL PRACTICE GUIDELINE
Tomohiro Ishii, Kenichi Kashimada, Masanobu Kawai, Tomoyo Itonaga, Takeshi Iwasa, Akari Utsunomiya, Kayo Ozaki, Kazuhiro Kawamura, Junko Kanno, Jun Koh, Yoshiyuki Kojima, Shoko Sasaki, Hiroyuki Sato, Koji Shiraishi, Yasuhiro Naiki, Mitsuru Nishiyama, Takashi Hamajima, Yasuko Fujisawa, Noriko Makita, Katsuyuki Matsui, Toshihiro Yanai, Reiko Horikawa, Tsutomu Ogata
Vol 73 Issue 2 (February, 2026)
Recommendation from the Editor in Chief
Hypoparathyroidism is a rare disease caused by shortage of action of parathyroid hormone (PTH). Importantly, patients affect not only circulating imbalance between calcium (Ca) and phosphate (P) but also systemic severe complications. However, managements for Hypoparathyroidism have long remained traditional supplementation of Ca and active form of vitamin D without correction of considerably low level of PTH. In this issue, Dr. Kenji Ashida, Dr. Yasuhiro Takeuchi and colleague provide us with well-organized, state-of-the-art original article on phase 3 Japan trial of palopegteriparatide, a potent pro-drug of PTH administered once daily via subcutaneous injection. Our editorial team would greatly appreciate if readers go over the article and enjoy the true pleasure of cutting edge clinical endocrinology.